This is a randomized controlled pilot study to evaluate the effects of intermittent caloric restriction compared with low carbohydrate diet in youth with cardiometabolic risk.
The National China Health and Nutrition Survey revealed that 42% of overweight children had at least one cardiovascular metabolic risk, such as hyperglycaemia, dyslipidemia or hypertension. Non-pharmaceutical life style modifications are the recommended intervention to these subjects, including caloric restriction and increased physical activity. However, the problems of poor compliance and metabolic adaptation are well known. Evidences from a number studies in rodent models and human indicated that intermittent caloric restriction (ICR) may stimulate series reactions in human body, including improvement of insulin sensitivity, blood pressure, oxidative stress and inflammation, and may be easier to follow. Evidence from larger human studies is strongly encouraged, while the effects, safety and adherence in chidren and youth need to be studied. This study is a randomized controlled trial of intermittent caloric restriction versus low carbohydrate diet in youth with cardiometabolic risk over one month period. The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week. For control group, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention during the 14-day intervention period,. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted. The study aim to explore effects of the dietary interventions on cardiometabolic markers, inflammatory reaction, oxidative stress and gut microbiome in youth with cardiometabolic risk.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
34
The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.
During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.
Children's Hospital of Fudan University
Shanghai, China
Reversal of cardiometabolic abnormalities
The primary outcome is a composite outcome that will be measured by combining multiple reverse outcomes of the following cardiometabolic abnormalities: (1) overweight or obesity, (2) prediabetes, (3) hyperlipidemia and (4) elevated blood pressure. It is defined as occurring if any cardiometabolic abnormality has a reversal outcome at the 14th day of dietary intervention phase. Reversal of cardiometabolic abnormalities is defined as: At the 14th day of dietary intervention phase, at least one of the following indicators changed from abnormal at baseline to normal: overweight, obesity, prediabetes, hyperlipidemia and elevated blood pressure. (The reversal of overweight or obesity is defined according to reference\[1, 2\]: For subject with general obesity at baseline: weight loss of 1.5 kg after intervention; For subject with central obesity at baseline: waist circumference reduction of 1.5 cm after intervention.)
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in insulin
Serum from fasting blood sample is used for measurement of insulin.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in insulin-like growth factor-1
Fasting blood sample for measurement of insulin-like growth factor-1.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in mean blood glucose
Measured by a blood glucose monitor for 24-hour glucose monitoring during the 14-day intervention phase.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in gut microbial compositions
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
Stool sample of subject is used for measurement of gut microbial compositions.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in body weight
Body weight is measured according to the Physical Fitness and Health Surveillance of Chinese School Students by trained, certified study staff. It is measured to the nearest 0.1 kg.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in body weight
Body weight is measured by subject and reported by electronic questionnaire. It is measured to the nearest 0.1 kg.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase.
Change in waist circumference
Waist circumference is measured to the nearest 0.1 cm using a constant tension tape around the waist at 1 cm below the navel as the subject exhaled. It is calculated as the average value of two measurements.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in waist circumference
Waist circumference is measured by subject and reported by electronic questionnaire. It is measured to the nearest 0.1 cm using a constant tension tape around the waist at 1 cm below the navel as the subject exhaled. It is calculated as the average value of two measurements.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase.
Dietary energy intake
Daily dietary energy intake (kcals/day) is calculated by researchers using food weighing photos of the subject.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Self-reported dietary adherence
Adherence to diet will be assessed with a electronic questionnaire in the self-maintenance phase.
Time frame: At the 14th day of the self-maintenance phase.
Change in monocyte chemoattractant protein-1 (MCP-1)
MCP-1 will be measured by enzyme-linked immunosorbent assays (R\&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in free fatty acid (FFA)
FFA will be measured by enzyme-linked immunosorbent assays (R\&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
Change in fibroblast growth factor 21 (FGF-21)
FGF-21 will be measured by enzyme-linked immunosorbent assays (R\&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
Time frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.